Figure 1
Figure 1. Expression and localization of oncogenic NRAS and its PTM mutants. (A) Schematic diagram of retroviral expression vectors used to transduce NRASD12, NRASD12C181S, or NRASD12C186S. (B) Immunoblot of lysates of NIH3T3 cells stably expressing the vector control, NRASD12, NRASD12C181S or NRASD12C186S with a pan anti-RAS antibody (top band represents double Myc-tagged-NRAS; and bottom band, endogenous Ras). (C) NIH3T3 cells expressing GFP-fused NRASD12, NRASD12C181S, or NRASD12C186S, costained with fluorescence-conjugated antibodies against Golgi (Golga-7) or ER (BIP) resident proteins, were visualized on a Leica TCS SP2 Spectral Confocal Microscope (original magnification, ×630).

Expression and localization of oncogenic NRAS and its PTM mutants. (A) Schematic diagram of retroviral expression vectors used to transduce NRASD12, NRASD12C181S, or NRASD12C186S. (B) Immunoblot of lysates of NIH3T3 cells stably expressing the vector control, NRASD12, NRASD12C181S or NRASD12C186S with a pan anti-RAS antibody (top band represents double Myc-tagged-NRAS; and bottom band, endogenous Ras). (C) NIH3T3 cells expressing GFP-fused NRASD12, NRASD12C181S, or NRASD12C186S, costained with fluorescence-conjugated antibodies against Golgi (Golga-7) or ER (BIP) resident proteins, were visualized on a Leica TCS SP2 Spectral Confocal Microscope (original magnification, ×630).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal